Boryung Pharmaceutical Changes Company Name to 'Boryung' Inc... 'Third-Generation Founder' Kim Jeonggyun Takes Full Management Role

[Asia Economy Reporter Lee Gwan-joo] Boryung Pharmaceutical held its regular general meeting of shareholders on the 25th and approved the proposal to change its company name from ‘Boryung Pharmaceutical Co., Ltd.’ to ‘Boryung Corp.’

The company explained, “Amid a changing environment, we decided to change the company name to expand more growth and investment opportunities not only in the domestic pharmaceutical industry but also in the global market and the overall healthcare industry.”

Along with the approval of the name change, a new CI was also established. Through subsequent change procedures, the new company name and CI will be applied to products starting next month.

Additionally, at this general meeting, Boryung Pharmaceutical appointed Kim Jeong-gyun, CEO of Boryung Holdings, and Kim Seong-jin, head of Boryung Pharmaceutical’s Global Investment Center, as inside directors, and Cha Tae-jin, advisor at AIA Life, as an outside director. After the general meeting, the board of directors appointed Kim Jeong-gyun (newly appointed) and Jang Du-hyeon (reappointed) as co-CEOs. Accordingly, Boryung Corp. will operate under a dual CEO system with Kim Jeong-gyun and Jang Du-hyeon.

Furthermore, to enhance transparency and efficiency through board-centered management, the related board regulations were newly revised, and according to the new board regulations, CEO Kim Jeong-gyun was appointed as the chairman of the board.

This content was produced with the assistance of AI translation services.